Form 4: Outset Medical EVP sell-to-cover of 247 shares

On Nov. 17, 2025, EVP Marc Nash sold 247 OM shares at $4.60 in a sell-to-cover tied to RSU vesting, retaining 48,268 shares.

Summary

• Executive Vice President Marc Nash executed a sell-to-cover of 247 Outset Medical (OM) shares on 11/17/2025 at $4.60 per share.
• Transaction was solely to satisfy tax withholding from the vesting of an aggregate 674 RSU shares.
• Post-transaction beneficial ownership stands at 48,268 shares.
• The vested RSUs were originally granted on 03/15/2023, 07/24/2023, and 01/12/2024.
• The transaction was characterized as non-discretionary and conducted to meet tax obligations.

Sentiment

Score: 6

Explanation: Neutral-to-slightly positive administrative transaction: equity is vesting and insider retains a sizable stake, with the sale limited to tax withholding.

Positives

• Non-discretionary sell-to-cover indicates the sale was for tax withholding, not an elective disposition.
• Executive retains a meaningful stake of 48,268 shares after the transaction.
• RSU vesting (674 shares) reflects ongoing equity compensation alignment.

Negatives

• Insider sale occurred (247 shares), which some investors may view cautiously despite the tax-related nature.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares were sold solely to satisfy tax withholding obligations from RSU vesting.
• The transaction was a 'sell to cover' and does not represent a discretionary trade.

Industry Context

Sell-to-cover transactions upon RSU vesting are routine across U.S. public companies, including medtech peers, and typically reflect administrative tax settlement rather than a view on company fundamentals.

Comparison to Industry Standards

• The small-size, tax-driven sell-to-cover is consistent with standard practice seen at medtech peers such as Medtronic, Baxter, and Insulet during RSU vesting events.
• The transaction’s characterization as non-discretionary aligns with common administrative handling of equity award tax obligations across large-cap and mid-cap medical device companies.
• Post-transaction continued ownership (48,268 shares) is typical for executives retaining core equity exposure after vesting cycles.

Stakeholder Impact

• Minimal direct impact to shareholders given the small, non-discretionary nature of the sale.
• No operational or customer/supplier implications disclosed.
• Executive equity alignment maintained with 48,268 shares held post-transaction.

Key Dates

Keywords

Outset Medical, OM, Form 4, insider transaction, sell to cover, RSU vesting, beneficial ownership, Marc Nash, executive compensation, medical devices